"Thank you God and also the support of friends and companions so that this year I received the rank of 3rd Best Scientist in Indonesia for the Pharmacy and Pharmaceutical Sciences category and also received Top 3% in Indonesia for the Medical and Health Sciences category as well as publication citations," said Prof. Raymond, who also serves as the Director of Research and Business Development at Dexa Group, in a press release received by Dream.

Prof. Raymond then developed a career in drug research from synthetic organic materials since he acquired knowledge up to the level of Post Doctoral Fellow at the University of California, San Francisco. He can be called one of the first Indonesian sons to study genetic engineering in the 1980s era, because during that period, engineering science in the United States was just developing and in Indonesia it had not been fully explored yet.

Finally, in the early 2000s, Prof. Raymond was called back to the homeland and embarked on a career at the leading pharmaceutical company, PT Dexa Medica. At that time, the founder of PT Dexa Medica, the late Rudy Soetikno, had a vision to develop medicines from Indonesia's natural resources. Then, in 2005, Prof. Raymond and the scientists at DLBS developed OMAI, which continues to this day. OMAI is a pharmaceutical product that Indonesia takes pride in, as it has a Domestic Component Level (TKDN) of over 80% and has been exported to 10 countries across 3 continents.